Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.

BACKGROUND Aztreonam/avibactam is a combination agent that shows promise in treating infections caused by highly antibiotic-resistant MBL-producing Enterobacterales. This combination can be achieved by combining two FDA-approved drugs: ceftazidime/avibactam and aztreonam. It is unknown whether ceftazidime in the combination ceftazidime/aztreonam/avibactam has a synergistic or antagonistic effect on the in vitro activity of aztreonam/avibactam by significantly increasing or decreasing the MIC. OBJECTIVES To determine whether increasing ceftazidime concentrations affect the MICs of aztreonam/avibactam alone. METHODS A custom 8 × 8 chequerboard broth microdilution (BMD) panel was made using a digital dispenser (Hewlett-Packard, Corvallis, OR, USA). The panel included orthogonal 2-fold dilution series of aztreonam and ceftazidime ranging from 0.5 to 64 mg/L. Avibactam concentration was kept constant at 4 mg/L throughout the chequerboard. Thirty-seven Enterobacterales isolates from the CDC & FDA Antibiotic Resistance Isolate Bank or CDC's internal collection with intermediate or resistant interpretations to aztreonam and ceftazidime/avibactam were included for testing. All isolates harboured at least one of the following MBL genes: blaIMP, blaNDM or blaVIM. RESULTS Regardless of the concentration of ceftazidime, aztreonam/avibactam with ceftazidime MICs for all 37 isolates were within one 2-fold doubling dilution of the aztreonam/avibactam MIC. CONCLUSIONS Ceftazidime, in the combination ceftazidime/avibactam/aztreonam, did not affect the in vitro activity of aztreonam/avibactam in this sample of isolates. These findings can help assure clinical and public health laboratories that testing of aztreonam/avibactam by BMD can act as a reliable surrogate test when the combination of ceftazidime/avibactam and aztreonam is being considered for treatment of highly antibiotic-resistant MBL-producing Enterobacterales.

[1]  C. Elkins,et al.  Validation of Aztreonam-Avibactam Susceptibility Testing Using Digitally Dispensed Custom Panels , 2020, Journal of Clinical Microbiology.

[2]  M. T. Mechi,et al.  Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase–Producing Enterobacterales During a Regional Outbreak , 2020, Open forum infectious diseases.

[3]  R. Bonomo,et al.  REVIEWS OF ANTI-INFECTIVE AGENTS: Louis Saravolatz, Section Editor OF ANTI-INFECTIVE AGENTS Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations , 2022 .

[4]  F. Tubau,et al.  Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection , 2018, The Journal of antimicrobial chemotherapy.

[5]  M. Castanheira,et al.  Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates , 2017, Antimicrobial Agents and Chemotherapy.

[6]  K. Kazmierczak,et al.  In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015 , 2017, Antimicrobial Agents and Chemotherapy.

[7]  R. Humphries,et al.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? , 2017, Antimicrobial Agents and Chemotherapy.

[8]  Tse Hsien Koh,et al.  In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli , 2015, Antimicrobial Agents and Chemotherapy.

[9]  K. Kazmierczak,et al.  In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013 , 2015, Antimicrobial Agents and Chemotherapy.

[10]  M. Falagas,et al.  Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections , 2014, Emerging infectious diseases.

[11]  D. Ehmann,et al.  Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor , 2012, Proceedings of the National Academy of Sciences.